Nouscom
Nouscom is a privately-held immunotherapy company developing genetic neoantigen vaccines and oncolytic viruses for the prevention and treatment of cancer.
The company's research is based on its clinically validated Exovax platform and its lead program is NOUS-209, an off-the-shelf cancer vaccine based on shared frame-shift generated neoantigens. The preclinical product candidate, NOUS-100-PV, a personalized neoantigen-based vaccine, is also expected to enter clinical studies in 2019.
Nouscom is based in Basel, Switzerland, with operations in Rome, Italy, and is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
Latest Nouscom News & Features
9 September 2022
26 February 2020
23 January 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze